Publications by authors named "Anne Camez"

Claim this Profile
E
Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Clinical Trial.
Andrew Blauvelt, Craig L Leonardi, Melinda Gooderham, Kim A Papp, Sandra Philipp, Anne Camez

JAMA Dermatol· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adalimumab in Active and Inactive, Non-Infectious Uveitis: Global Results from the VISUAL I and VISUAL II Trials.
Hiroshi Goto, Masahiro Zako, Kenichi Namba, Noriyasu Hashida, Toshikatsu Kaburaki, Anne Camez

Ocul Immunol Inflamm· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lack of Effect of 12-Week Treatment with Risankizumab on the Pharmacokinetics of Cytochrome P450 Probe Substrates in Patients with Moderate to Severe Chronic Plaque Psoriasis.
Amit Khatri, Ling Cheng, Anne Camez, Stanislav Ignatenko, Yinuo Pang

Clin Pharmacokinet· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Efficacy of Adalimumab in Patients with Noninfectious Uveitis in an Ongoing Open-Label Study: VISUAL III.
Eric B Suhler, Alfredo Adán, Antoine P Brézin, Eric Fortin, Hiroshi Goto, Anne Camez

Ophthalmology· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corticosteroid-Related Adverse Events Systematically Increase with Corticosteroid Dose in Noninfectious Intermediate, Posterior, or Panuveitis: Post Hoc Analyses from the VISUAL-1 and VISUAL-2 Trials.
Eric B Suhler, Jennifer E Thorne, Manish Mittal, Keith A Betts, Samir Tari, Anne Camez

Ophthalmology· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Safety and Effectiveness of Adalimumab for Moderate to Severe Psoriasis: Results from 7-Year Interim Analysis of the ESPRIT Registry.
Alan Menter, Diamant Thaçi, Jashin J Wu, William Abramovits, Francisco Kerdel, Anne Camez

Dermatol Ther (Heidelb)· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial.
Quan Dong Nguyen, Pauline T Merrill, Glenn J Jaffe, Andrew D Dick, Shree Kumar Kurup, Anne A Camez

Lancet· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adalimumab in Patients with Active Noninfectious Uveitis.
Glenn J Jaffe, Andrew D Dick, Antoine P Brézin, Quan Dong Nguyen, Jennifer E Thorne, Anne Camez

N Engl J Med· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term safety and efficacy of adalimumab in Japanese patients with moderate to severe Crohn's disease.
Mamoru Watanabe, Toshifumi Hibi, Nael M Mostafa, Jingdong Chao, Vipin Arora, Anne Camez

J Crohns Colitis· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adalimumab induces deep remission in patients with Crohn's disease.
Jean-Frédéric Colombel, Paul J Rutgeerts, William J Sandborn, Mei Yang, Anne Camez

Clin Gastroenterol Hepatol· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis.
Yasuo Suzuki, Satoshi Motoya, Hiroyuki Hanai, Takayuki Matsumoto, Toshifumi Hibi, Anne Camez

J Gastroenterol· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adalimumab improves patient-reported outcomes and reduces indirect costs in patients with moderate to severe Crohn's disease: results from the CARE trial.
Edouard Louis, Robert Löfberg, Walter Reinisch, Anne Camez, Mei Yang

J Crohns Colitis· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial.
Paul Rutgeerts, Gert Van Assche, William J Sandborn, Douglas C Wolf, Karel Geboes, Anne Camez

Gastroenterology· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohn's disease.
Mamoru Watanabe, Toshifumi Hibi, Kathleen G Lomax, Susan K Paulson, Jingdong Chao, Anne Camez

J Crohns Colitis· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adalimumab produces clinical remission and reduces extraintestinal manifestations in Crohn's disease: results from CARE.
Robert Löfberg, Edouard V Louis, Walter Reinisch, Anne M Robinson, Martina Kron, Anne Camez

Inflamm Bowel Dis· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of propafenone sustained release in the prophylaxis of symptomatic paroxysmal atrial fibrillation (The European Rythmol/Rytmonorm Atrial Fibrillation Trial [ERAFT] Study).
Thomas Meinertz, Gregory Y H Lip, Fedrico Lombardi, Zigmunt P Sadowski, Brigitte Kalsch, Anne Camez

Am J Cardiol· December 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis